612 related articles for article (PubMed ID: 8640334)
1. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
2. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
3. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
4. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
5. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
6. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
7. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
Yu SM; Kuo SC
Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
[TBL] [Abstract][Full Text] [Related]
8. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
10. YC-1 potentiates the antiplatelet effect of hydrogen peroxide via sensitization of soluble guanylate cyclase.
Wu CC; Kuo SC; Lee FY; Teng CM
Eur J Pharmacol; 1999 Sep; 381(2-3):185-91. PubMed ID: 10554886
[TBL] [Abstract][Full Text] [Related]
11. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
12. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
13. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
[TBL] [Abstract][Full Text] [Related]
14. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets.
Ghigo D; Heller R; Calvino R; Alessio P; Fruttero R; Gasco A; Bosia A; Pescarmona G
Biochem Pharmacol; 1992 Mar; 43(6):1281-8. PubMed ID: 1348617
[TBL] [Abstract][Full Text] [Related]
17. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
18. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats.
Hsieh GC; O'Neill AB; Moreland RB; Sullivan JP; Brioni JD
Eur J Pharmacol; 2003 Jan; 458(1-2):183-9. PubMed ID: 12498924
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils.
Wang JP; Chang LC; Huang LJ; Kuo SC
Biochem Pharmacol; 2001 Sep; 62(6):679-84. PubMed ID: 11551512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]